Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. by Kanis, Ja et al.
REVIEW
Identification and management of patients at increased
risk of osteoporotic fracture: outcomes of an ESCEO expert
consensus meeting
J. A. Kanis1,2 & C. Cooper3,4 & R. Rizzoli5 & B. Abrahamsen6 & N. M. Al-Daghri7 &
M.L. Brandi8 & J. Cannata-Andia9 & B. Cortet10 &H. P. Dimai11 & S. Ferrari5 & P. Hadji12 &
N. C. Harvey3 & M. Kraenzlin13 & A. Kurth14,15 & E. McCloskey1,16 & S. Minisola17 &
T. Thomas18 & J.-Y. Reginster19 & for the European Society for Clinical and Economic
Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
Received: 13 February 2017 /Accepted: 10 March 2017
# International Osteoporosis Foundation and National Osteoporosis Foundation 2017
Abstract
Summary Osteoporosis represents a significant and increasing
healthcare burden in Europe, but most patients at increased
risk of fracture do not receive medication, resulting in a large
treatment gap. Identification of patients who are at particularly
high risk will help clinicians target appropriate treatment more
precisely and cost-effectively, and should be the focus of fu-
ture research.
Introduction The purpose of the study was to review data on
the identification and treatment of patients with osteoporosis
at increased risk of fracture.
Methods Aworking group convened by the European Society
for Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis met to review current data on the epidemiology
and burden of osteoporosis and the patterns of medical man-
agement throughout Europe.
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Results In Europe in 2010, the cost of managing osteoporosis
was estimated at €37 billion and notably the costs of treatment
and long-term care of patients with fractures were considerably
higher than the costs for pharmacological prevention. Despite
the availability of effective treatments, the uptake of osteopo-
rosis therapy is low and declining, in particular for secondary
fracture prevention where the risk of a subsequent fracture fol-
lowing a first fracture is high. Consequently, there is a signifi-
cant treatment gap between those who would benefit from
treatment and those who receive it, which urgently needs to
be addressed so that the burden of disease can be reduced.
Conclusions Implementation of global fracture prevention
strategies is a critical need. Future research should focus on
identifying specific risk factors for imminent fractures, periods
of high fracture risk, patients who are at increased risk of
fracture and therapies that are most suited to such high-risk
patients and optimal implementation strategies in primary,
secondary and tertiary care.
Keywords Fracture risk . Healthcare burden .Management .
Osteoporosis . Secondary prevention . Treatment gap
Introduction
Osteoporosis represents a substantial and increasing burden
on healthcare systems in many countries around the world.
The resulting fractures are associated with reduced quality of
life and significant morbidity, mortality and healthcare re-
source utilisation [1]. However, most patients who have
sustained a fracture or who are at increased risk of fracture
do not receive appropriate osteoporosis treatment, and treat-
ment rates have declined in recent years [1]. This increasing
‘treatment gap’ suggests the need for both better evaluation of
patients and consensus among clinicians regarding the defini-
tion of those at increased risk of fracture and how they should
best be treated. To address this, a working group convened by
the European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) met to review cur-
rent data on the epidemiology and burden of osteoporosis and
the patterns of medical management throughout Europe. This
manuscript summarises the working group’s views and rec-
ommendations regarding strategies for the identification of
patients at increased risk of fracture, the currently available
options for their effective management and data for new prod-
ucts in development.
Methods
As in previous initiatives and publications [2], the ESCEO
working group consisted of clinical scientists and experts in
the field of osteoporosis. Different members of the ESCEO
working group were asked to prepare a full review of the liter-
ature on the following: (a) Epidemiology of spinal and non-
spinal fractures in Europe (CC); (b) Burden of spinal and non-
spinal fractures in Europe (MLB); (c) Management of osteopo-
rosis in Europe—the treatment gap (JAK); (d) How can we
define a patient at high (imminent) risk of fracture (NCH);
and (e) Efficacy of currently available treatments in patients
at high risk of fracture (TT). Each member prepared a list of
the most important topics based on their review of the literature
and then made a set of preliminary recommendations. The
subsequent step was a face-to-face meeting for the whole group
(9 September 2016) to make amendments and discuss further
recommendations. The plan of the manuscript was also
discussed, and shared conclusions were reached. The present
recommendations were developed independently of any of the
funding sources that had no role in the decision to prepare this
document and its implementation, revisions and approval for
publication. In addition, each member of the task force individ-
ually agreed to declare their potential conflict of interest, if any,
in the process of article submission.
Epidemiology of vertebral and non-vertebral
fractures in Europe
More than 8.9 million osteoporotic fractures occur annually
worldwide, and approximately one third of those fractures are
in Europe, equating to 3.5 million cases per year [1]. A review
of the clinical and economic burden of osteoporotic fractures
in 27 European countries in 2010 found that two thirds of all
incident fractures occurred in women and fracture incidence
increased with age, with the majority of hip fractures reported
in patients aged ≥80 years [1]. The most common fractures
were hip (18%), forearm (16%), vertebral (15%) and ‘others’
(51%) (Fig. 1) [1]. Other studies, such as the POSSIBLE EU®
study, have also highlighted the importance of non-hip and
non-vertebral (NHNV) fractures, where 70% of fractures oc-
curred in NHNV locations in postmenopausal women receiv-
ing bone loss therapies in a primary care setting [3].
Historically, the importance of vertebral fracture incidence
has been relatively inflated due to its use as a primary endpoint
in many clinical studies, where too much emphasis has been
placed on the importance of grade 1 vertebral fractures. While
such vertebral deformities may have some prognostic value
for further vertebral fractures, they have little or no prognostic
value for non-vertebral fractures; therefore, more focus should
be placed on grade 2 and 3 fractures [4]. With the increasing
prominence of non-vertebral fracture incidence as a discrimi-
nator between investigational drugs in more recent clinical
studies, a balance between the relative significances of differ-
ent fracture types is needed.
Geographically, fracture incidence varies widely by coun-
try across Europe (Fig. 1) [1, 5]. Compared with other regions
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of the world, Europe has some of the highest hip fracture rates,
with an apparent north–south gradient, and most countries are
categorised as high or moderate risk [5]. However, this varia-
tion between countries is not as pronounced for vertebral frac-
ture incidence [6], at least when judged by vertebral mor-
phometry. The underlying causes of these variations are un-
known but are likely to be environmental rather than genetic
[5]. Socioeconomic factors have been hypothesised as being
the most likely explanation for the heterogeneity of fracture
incidence between communities, but other factors are also
candidates, such as sunlight exposure, low calcium intake,
physical activity, low body mass index, anthropometric vari-
ables and race [1, 7, 8].
Substantial temporal trends in age-specific rates of hip frac-
ture have been observed in recent decades. With a few excep-
tions, age-specific incidence rates rose in western populations
until around 1980 and have since either reached a plateau or
declined [6]. In the case of hip fracture incidence rates, an
earlier reversal of this trend along with a higher peak fracture
incidence has been demonstrated in northern European coun-
tries compared with a later trend for reversal and lower peak
fracture incidence in some southern European countries [9]. A
recent study of hip fracture trends in Sweden and Denmark
found that period and cohort effects, which may reflect envi-
ronmental and lifestyle factors, contributed to this observa-
tion, and analyses indicated that age-specific hip fracture rates
were likely to increase again in the near future [10].
Further to this, the total number of people with osteoporo-
sis in Europe has been predicted to rise by 23%, from 27.5
million in 2010 to 33.9 million in 2025 due to the increasing
proportion of elderly people in the population. As a conse-
quence, the osteoporotic fracture rate is also expected to in-
crease throughout Europe, with an increase of 56 and 41%
predicted in the male and female populations, respectively [1].
Burden of vertebral and non-vertebral fractures
in Europe
Hip and vertebral fractures are associated with increased mor-
tality, with the mortality risk highest immediately after the
fracture event and then decreasing with time [11]. In Europe,
the number of deaths in 2010 directly related to fractures was
estimated at approximately 20,100 in men and 22,700 in
women, of which 49 and 33% were attributed to hip and
vertebral fracture events, respectively [1].
The management of osteoporosis is also associated with a
very high economic burden in Europe, with a high degree of
variation between countries (Fig. 2). In 2010, the cost of man-
aging osteoporosis was estimated at €37 billion. Despite this,
there is currently minimal investment in pharmacological pre-
vention, which comprised 5% of this cost, compared with the
costs of treating incident fractures (66%) and long-term frac-
ture care (29%) [1]. As a proportion of the total spend,
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excluding expenditure for pharmacological prevention, hip
fractures represented 54%, while ‘other fractures’ represented
39%, and clinical vertebral and forearm fractures only repre-
sented 5 and 2%, respectively [1]. The significant impact of
NHNV fractures in particular on costs and healthcare re-
sources has also been demonstrated in other studies, such as
the Global Longitudinal Study of Osteoporosis in Women
(GLOW) study where NHNV fractures resulted in a substan-
tially higher number of days in hospital and rehabilitation/
nursing home care over a 1-year period compared with verte-
bral and hip fractures [13].
When considering quality-adjusted life-years (QALYs),
which give a societal perspective on the burden of disease,
the total health burden of osteoporosis in Europe in 2010
was estimated at 1,165,000 QALYs, and twice as many
QALYs were lost in women compared with men [1]. Hip
fractures, clinical vertebral, forearm and other fractures in-
curred approximately 600,000 (52%), 344,000 (30%),
19,000 (2%) and 202,000 (17%) QALYs lost, respectively.
For hip and vertebral fractures, approximately 79 and 59%
of the QALYs lost were a consequence of prior fractures [1].
When the cost of osteoporosis was combined with the value
for QALYs lost, the overall cost of osteoporosis amounted to
€98 billion in Europe in 2010.
This burden associated with osteoporosis has been shown
to be higher than for other common non-communicable dis-
eases. Total disability-adjusted life-years (DALYs) lost due to
osteoporosis in Europe, reflecting the years of life lost due to a
fracture and the disability in those who survive, were 5.8 mil-
lion in 2010, representing 0.83% of the global burden of non-
communicable disease. This loss in DALYs for osteoporosis
was greater than for other diseases such as hypertensive heart
disease and rheumatoid arthritis [1]. Furthermore, fractures
due to osteoporosis accounted for more deaths and morbidity
than any cancer type other than lung cancer [1].
The already high healthcare costs of osteoporosis in Europe
are predicted to increase in the future due to the growing
elderly population. The annual number of QALYs lost annu-
ally in Europe is expected to rise, such that by 2025, it will
have increased by 20% from 2010, with the highest growth
(32%) forecast for the population aged ≥80 years, who incur
the highest costs for fractures compared with other age groups
[1]. Overall, the total cost (including values of QALYs lost) in
Europe is predicted to rise by 23%, from €98 billion in 2010 to
€120 billion in 2025.
It is apparent that the very high costs associated with oste-
oporosis and its management in Europe, coupled with the
predicted future cost increases, highlight the critical need for
a change in healthcare policy and the importance of
implementing preventative strategies to reduce this high bur-
den of disease.
Management of osteoporosis in Europe:
the treatment gap
Approximately 6.8 million men and women in Europe had
sustained a prior hip or clinical vertebral fracture in 2010
[1]. It is well known that the risk of a subsequent fracture
increases significantly following a first fracture [14–17], yet
despite this and the advances in osteoporosis treatment, pa-
tients with a prior fracture are reported to have a low uptake of
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treatments for secondary prevention of fracture and indeed,
worldwide [1, 18–23]. Prospective and observational studies,
including data from the GLOW study, suggest that only 20%
of eligible patients receive osteoporosis treatment after frac-
ture, although uptake varies widely by country in Europe [1,
18]. Of great concern is that treatment uptake has also been
shown to be decreasing over time [1]. In a retrospective, ob-
servational cohort study in the USA, the estimated probability
of osteoporosis medication use in the year after hip fracture
declined significantly from 40 to 21% over the 10-year study
period [19]. Treatment use was also lower in older patients
than younger patients [19], demonstrating that those who
needed treatment the most are maybe the least likely to receive
it.
In Europe, there was a general trend towards an increase in
treatment uptake until 2006–2008, after which there was a
plateau and subsequent decrease in many countries up to
2010–2012, most markedly for bisphosphonates; non-
bisphosphonate use had a continuing modest increase [1, 24]
(Fig. 3). A similar trend has been observed in the USA [25].
Uptake of osteoporosis treatments varies substantially be-
tween countries in Europe, generally being lower than average
in northern and eastern Europe (with the exception of Ireland
and Hungary), while western Europe has the highest coverage
[1]. Added to this is the influence of patient adherence to
treatment, as demonstrated in a Swedish study where approx-
imately 50% of all treatment-naïve patients discontinued treat-
ment for osteoporosis within 1 year [26].
Various approaches, using for example prescription claims
data, can be used to characterise the treatment gap: the pro-
portion of patients treated in relation to those eligible for treat-
ment based on their fracture risk. The probability of fracture
can be assessed using FRAX, which integrates the weight of
clinical risk factors for fracture, with or without information
on bone mineral density (BMD), to give the 10-year
probability of hip fracture or a major osteoporotic fracture
(MOF) (clinical spine, hip, forearm or humerus) [27]. As
FRAX country models are calibrated for fracture incidence,
there is a large expected heterogeneity between countries in
the probability of fracture [1, 5]. Furthermore, an intervention
threshold must be defined to be able to characterise the treat-
ment gap, e.g. the FRAX-based UK National Osteoporosis
Guidelines Group intervention threshold of a 10-year fracture
probability equivalent to women with a prior fragility fracture
without knowledge of BMD [27], which is increasingly being
adopted in country-specific assessment guidelines [28].
Using FRAX to determine the 10-year probability of a
MOF for women at the fracture threshold, a significant treat-
ment gap has been identified in Europe (Fig. 4), with only
59% of men and 57% of women receiving treatment out of
the population considered eligible for treatment [1]. A large
degree of heterogeneity is evident between countries, with the
treatment gap for women ranging from 95% in Bulgaria to
25% in Spain. There are multiple reasons underlying this large
treatment gap, such as clinicians not adhering to treatment
guidelines and reimbursement issues. Another contributor is
poor patient adherence to treatment, which may be influenced
by the fact that older patients often have comorbidities and
need to takemultiple medications. Also, some treatments have
only moderate efficacy; studies of goal-directed treatment in
osteoporosis have highlighted difficulties inmeeting treatment
goals with existing therapies in high-risk patients [29].
Furthermore, some treatments require frequent dosing or are
associated with side effects, which can result in patients being
reluctant to persist with treatment [27]. This has been illustrat-
ed in recent years by the overly negative reaction of the med-
ical community and lay press to reports of rare side effects of
bisphosphonates, such as osteonecrosis of the jaw, atrial fibril-
lation, atypical femur fracture and oesophageal cancer, which
have concerned patients and discouraged general practitioners
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from prescribing bisphosphonates, therefore impacting on up-
take of these treatments [30]. Reports of osteonecrosis of the
jaw with bisphosphonates have also resulted in an overreac-
tion from the dental community. Consequently, and in contrast
to that observed for generic medications in other diseases (i.e.
statins for hypercholesterolaemia), the availability of generic
bisphosphonates has had little impact on treatment uptake [1,
25]. Furthermore, general practitioners may still perceive ther-
apies for osteoporosis as being too expensive. Another reason
for the treatment gap may be that, unlike some other chronic
diseases such as diabetes, patients do not see an immediate
change in their condition and some may not understand pa-
rameters used to monitor their condition, such as biomarkers
or BMD. Comparisons between the efficacy of osteoporosis
drugs in preventing poor outcomes and mortality and the ef-
ficacy of treatments for other chronic diseases should be
emphasised in order to correct the misperception that osteo-
porosis is not a serious disease and that osteoporosis drugs are
similarly effective as those in other conditions.
Strategies are urgently needed to be implemented to close
the treatment gap. Firstly, as they are recognised to be at great-
er risk of a second fracture, patients with a prior fracture
should be assessed and managed appropriately. Screening
programmes to identify patients at increased risk of fracture
are currently being evaluated for their effectiveness in reduc-
ing fracture incidence. The SCOOP study in the UK was a
seven-centre, randomised, controlled study with 5-year fol-
low-up that assessed the effectiveness of a community-based
screening programme using FRAX to assess women at high
risk of hip fracture [31]. The study confirmed the feasibility of
screening in the UK, and while investigators did not observe
an overall reduction in fracture rates or mortality, hip fracture
rates were significantly reduced by nearly 30%.
Further education is also needed for both healthcare pro-
fessionals and patients to encourage adherence to publish
treatment guidelines and to put into context the perceived
versus actual risks of reported bisphosphonates side effects.
Clearer communication to patients regarding monitoring
methods will also be of value so that they understand the
effects of their treatment and importance of adherence.
Finally, efforts to close the treatment gap may be further
enhanced by implementing fracture liaison services, which
have been shown to improve uptake of osteoporosis interven-
tion guidelines, reduce re-fracture rates and increase the cost-
effectiveness of treatment [22, 32–34]. Global initiatives, such
as the International Osteoporosis Foundation’s (IOF) ‘Capture
the Fracture®’ campaign, aim to develop a best practice
framework for fracture liaison services and provide support
and resources that facilitate their implementation at a local
level. Furthermore, the clinical community in Europe needs
to learn from healthcare systems in countries, where the treat-
ment gap is low, to develop a more consistent approach to
osteoporosis care.
How can we define a patient at increased risk
of fracture?
First, we should consider what we mean by an increased risk
of fracture and what time scale would be appropriate for this
metric. Were we able to deliver entirely safe and cost-effective
interventions with high adherence, then lifelong interventions
might be envisaged. Given that this is not (yet) possible, then
targeting treatment to those at high risk becomes an inevita-
bility. Compared with the young, the elderly are at greatly
increased risk of fracture [35] and women are at increased risk
compared with men [1]. The risk of fracture is also higher in
those with low BMD and in those who are prone to falling or
have sustained prior low-energy fractures [1, 15, 36]. As the
efficacy of pharmaceutical intervention for osteoporosis has
been tested in, at best, studies of 5 or 10 years’ duration, these
are more intuitive time scales over which to address fracture
risk than, for example, lifetime risk of fracture.
Whereas there are many possible predictors of incident
fracture, the time course of the relationship of these risk fac-
tors with fracture is currently still uncertain.What we do know
is that previous fracture at different sites is a well-documented
risk factor for future fracture, and this risk is highest immedi-
ately after the initial event and subsequently declines with
time [14–17] (Fig. 5). This has recently been demonstrated
in the Reykjavik study, where the risk of a MOF after a first
MOF was 2.7-fold higher compared with the population risk
at 1 year, decreasing to 1.4-fold after 10 years [14]; this higher
risk of a second MOF increased by 4% for each year of age.
Furthermore, prior fractures continue to be an important pre-
dictor of fracture risk for up to 10 years, even in models ad-
justed for age, BMD and other FRAX clinical risk factors
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[37]. Further studies are needed to analyse the determinants of
imminent risk, e.g. whether the type of fracture affects the
future risk, and whether the risks identified are responsive to
medical intervention.
Efficacy of currently available treatments in patients
at increased risk of fracture
A range of therapies are approved, with others under investi-
gation for the prevention and treatment of osteoporosis [27].
They are broadly divided into two categories: inhibitors of
bone resorption by osteoclasts (including bisphosphonates,
selective oestrogen receptor modulators and monoclonal anti-
bodies to the receptor activator of nuclear factor kappa-B li-
gand) and anabolic agents that stimulate bone formation, such
as teriparatide (parathyroid hormone [PTH] 1–34). Strontium
ranelate is another agent that reduces fracture risk. The mech-
anism of action of strontium ranelate remains unclear, but it
appears to have weak effects on bone turnover and changes in
bone quality. In the clinical study setting, different approaches
are used to evaluate the efficacy of these approved and inves-
tigational treatments in patients at high risk of fracture, includ-
ing the selection of such patients using specific inclusion
criteria, subgroup analysis using risk factors known to further
increase fracture risk or analyses using a continuous variable
of fracture probability, such as FRAX.
Differences in clinical study inclusion criteria, as well as
baseline disease severity, can result in challenges when evaluat-
ing the optimal treatment for patients at increased risk of fracture
[38]. For example, the phase 3, double-blind, randomised,
placebo-controlled Abalopartide comparator trial in vertebral
endpoints (ACTIVE) study evaluating the investigational drug
abaloparatide recruited patients at low risk of fracture [39] com-
pared with others, such as the TROPOS and SOTI studies [40,
41], which evaluated the safety and efficacy of strontium
ranelate in patients with baseline characteristics that were more
indicative of a higher risk population. These two examples high-
light the discordances that can arise because of variable inclu-
sion criteria, resulting in different population characteristics,
which can make data comparison and interpretation difficult.
Broad inclusion criteria in positive clinical studies enable
analyses to be performed to investigate interactions between
baseline risk factors, such as FRAX,BMD, age or prior fractures
and treatment response. These analyses require a sufficiently
large number of high-risk patients to provide a meaningful un-
derstanding of the effect of treatment in such patients. Some
subgroup analyses from clinical studies have shown at least
comparable efficacy in patients at increased risk of fracture com-
pared with the overall population. For example, analyses of the
effect of baseline age, vertebral BMD and prevalent vertebral
fractures on the therapeutic effect of abaloparatide in postmen-
opausal women with osteoporosis did not reveal any differences
between those groups at increased risk and the high-risk popu-
lation [42]. However, most analyses have suggested improved
results in high-risk subgroups, including clinical studies of
teriparatide [43] and denosumab [44]. In contrast, a few studies
have suggested the reverse effect, including the randomised,
blinded, placebo-controlled MORE study, which demonstrated
that raloxifene had a greater effect in reducing vertebral fracture
risk in postmenopausal women with low BMD and no pre-
existing fractures versus those with pre-existing fractures at
baseline [45]. Differences were also observed when subgroups
for analyses were defined using different criteria. For example,
in the randomised, placebo-controlled HIP study, risedronate
reduced the risk of hip fracture in the subgroup of women with
confirmed osteoporosis, but not among women selected primar-
ily based on non-skeletal risk factors other than low BMD [46].
There are, however, some inherent limitations to subgroup
analyses. These include the loss of statistical power compared
with the original study design, which can lead to a high risk of
false-positive results and misinterpretation, and the fact that the
results are also dependent on the cut-off point used for analysis.
In most analyses, even when results appear different between
subgroups, interaction tests were non-significant. It should there-
fore be highlighted that primary endpoint results provide the
greatest weight of evidence in clinical studies, whereas subgroup
analyses, particularly when undertaken posthoc, can provide use-
ful information, but are lower in the hierarchy of evidence grades.
Some of the pitfalls of subgroup analyses can be avoided by
assessing the efficacy of a treatment as a continuous function
of fracture risk using BMD or FRAX [47]. To date, results
from posthoc analyses exploring the relationship between the
efficacy of osteoporosis medication and baseline fracture prob-
abilities assessed with FRAX have shown differences between
interventions. Studies of treatment with clodronate [48],
bazedoxifene [49] and denosumab [50] have shown larger re-
ductions in fracture incidence with increasing baseline FRAX
fracture probability in postmenopausal women. The finding of
greater efficacy at higher fracture probabilities has important
implications for health technology assessments, as treatments
should ideally be targeted to high-risk patients so greater effi-
cacy in the higher-risk groups could improve the budget impact
and the cost-effectiveness of interventions. In contrast, other
studies assessing treatment with raloxifene [49, 51], strontium
ranelate [52], abaloparatide [53] and teriparatide [54, 55] have
shown no significant interaction between treatment efficacy
and baseline fracture probability assessed using FRAX.
In terms of future research, further clinical efficacy data
supported by health economic assessments are needed so that
clinicians, regulatory bodies and payers can identify which
treatments are most effective in terms of clinical efficacy, safety
and cost for those patients at increased risk of fracture [56, 57].
To date, few studies have evaluated the effect of treatment in
patients with an increased risk of fracture immediately follow-
ing a first event of fracture, a period during which they are at
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highest risk. Importantly, the HORIZON study demonstrated
that infusion of zoledronic acid ≥2 weeks after hip fracture
repair resulted in hip BMD increases, significant reductions in
subsequent vertebral, non-vertebral and hip fracture risk and
reducedmortality [58]. Further studies are also needed to assess
the cost-effectiveness of early secondary prevention strategies
in addition to the clinical outcomes. Similarly, few studies have
yet demonstrated the efficacy of treatment in patients with an
increased risk of fracture related to a high risk of falls.
Given the current lack of clear evidence and the difficulties
in identifying treatments that have the best outcomes in pa-
tients at increased fracture risk, it is recommended that current
treatments for osteoporosis should demonstrate efficacy in
reducing the risk of both vertebral and non-vertebral fractures.
What can we expect from emerging agents
for the management of patients at increased risk
of fracture?
Although there is a range of osteoporosis treatments available,
as previously noted, some have only moderate efficacy, are
associated with significant side effects and/or require regular
and somewhat complex dosing regimens [27, 59]. Thus, there
is still an unmet need for new agents that provide more effec-
tive fracture prevention and are well tolerated, particularly in
those patients who have had a prior fracture and are at in-
creased risk of a subsequent fracture during the first year. As
noted in a recent review of future approaches for patients at
high risk of hip fracture, any new pharmacotherapy should
ideally aim to restore both trabecular and cortical bone
strength and be used in addition to lifestyle interventions, fall
prevention and potentially surgical intervention [59–61].
One drug currently under regulatory review is abaloparatide,
a synthetic analogue of human PTH-related protein (PTHrP),
which acts as a selective activator of the PTH type 1 receptor
(PTHR1) signalling pathway [62]. Abaloparatide has been in-
vestigated in the randomised, double-blind, placebo-controlled,
phase 3 ACTIVE study, which included an open-label
teriparatide comparator arm [39]. In a population of postmeno-
pausal osteoporotic women, abaloparatide given for 18 months
significantly reduced the risk of new vertebral fractures (primary
endpoint) by 86% compared with placebo (Fig. 6a), and signif-
icantly reduced the risk of non-vertebral fractures, MOFs and
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clinical fractures by 43, 70 and 43%, respectively. Abaloparatide
was also associated with modestly higher BMD gains, particu-
larly at cortical bone-rich sites, compared with teriparatide. The
incidence of hypercalcaemia was lower with abaloparatide than
teriparatide, consistent with the postulated lower bone resorption
with abaloparatide, and no differences in adverse events were
observed between the treatment groups.
Romosozumab is another osteo-anabolic compound under
investigation for the management of osteoporosis. It is a mono-
clonal antibody that binds to and inhibits sclerostin, a glycopro-
tein produced by osteocytes that has an important role as a
regulator of bone formation due to its inhibitory actions on
the Wnt signalling pathway [64]. The phase 3, randomised,
double-blind, placebo-controlled FRAME study evaluated
treatment with romosozumab in postmenopausal osteoporotic
women [63]. Patients were randomised to romosozumab or
placebo for 12 months; thereafter, all patients received open-
label denosumab for a further 12 months. Monthly subcutane-
ous injections of romosozumab were found to reduce the inci-
dence of new vertebral fractures at 12 and 24 months compared
with placebo. At 12 months, romosozumab significantly re-
duced the risk of new vertebral fractures and clinical fractures
by 73 and 36%, respectively, compared with placebo (Fig. 6b).
Romosozumab also reduced the risk of non-vertebral fractures
by 25%, although this was not significantly different versus
placebo. When patients from low-risk countries were excluded,
significant effects on non-vertebral fractures were observed,
suggesting that there may be a significant interaction between
fracture probability and efficacy. The cumulative 24-month in-
cidence of new vertebral fracture was significantly lower in the
group previously treated with romosozumab than in those treat-
ed with placebo, although no significant difference in non-
vertebral fracture was observed. Romosozumab was also asso-
ciated with increases in BMD at the lumbar spine, total hip and
femoral neck compared with placebo at 12 months, and these
gains were further increased after transition to denosumab.
Adverse events were balanced across the treatment groups,
and although serious hypersensitivity reactions were observed
with romosozumab, these were uncommon. Rare cases of
osteonecrosis of the jaw and atypical femoral fracture were
observed, although they had confounding factors that may have
contributed to the events. The development of romosozumab
therefore constitutes another promising option for the manage-
ment of osteoporosis in high-risk patients.
Conclusions
Osteoporosis represents a significant healthcare burden in
European countries which, due to the increasing number of el-
derly people, is predicted to rise further in the future. Despite this
outlook, most patients at increased risk of fracture, such as those
with a prior fracture, do not receive medication, resulting in a
large treatment gap that urgently needs to be addressed.
Identification of other potential fracture risk factors and of pa-
tients who are at particularly high risk of fracture during a certain
time period, e.g. in the year after a fracture, will help clinicians
target appropriate treatment more precisely and cost-effectively,
and should be the focus of future research and clinical study
endpoints. The new therapeutic bone-forming agents that are
currently in development and have shown promising results will
hopefully add to the treatment options available to clinicians.
Early adoption of effective fracture prevention strategies
targeted to patients at increased risk of fracture is critical to
reducing the healthcare burden of osteoporosis. Ongoing global
initiatives, such as the International Osteoporosis Foundation’s
‘Capture the Fracture®’ campaign, aim to develop a best prac-
tice framework that will act as an international benchmark for
fracture liaison services throughout the world, and endeavour to
provide support and resources that will facilitate their implemen-
tation at a local and national level. Ultimately, such strategies
will help close the current gap in secondary fracture prevention.
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